Checkpoint Therapeutics, Inc. (CKPT)
Automate Your Wheel Strategy on CKPT
With Tiblio's Option Bot, you can configure your own wheel strategy including CKPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CKPT
- Rev/Share 0.0
- Book/Share 0.2724
- PB 15.6397
- Debt/Equity 0.0
- CurrentRatio 1.9119
- ROIC -3.4623
- MktCap 367723200.0
- FreeCF/Share -0.607
- PFCF -10.1265
- PE -4.51
- Debt/Assets 0.0
- DivYield 0
- ROE 9.1624
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CKPT | D. Boral Capital | -- | Buy | -- | $9 | Jan. 13, 2025 |
News
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to d.
Read More
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Published: March 14, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to determ.
Read More
Checkpoint Therapeutics shares pop on acquisition by Sun Pharma
Published: March 10, 2025 by: Proactive Investors
Sentiment: Positive
Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments.
Read More
About Checkpoint Therapeutics, Inc. (CKPT)
- IPO Date 2016-12-19
- Website https://www.checkpointtx.com
- Industry Biotechnology
- CEO Mr. James F. Oliviero III, C.F.A.
- Employees 24